The drug industry's voice for manufacturing excellence
Production
Development
Information Technology
Compliance
Quality & Risk
Sections
Production
Development
Information Technology
Compliance
Quality & Risk
Facilities
Sectors
Special
Webinars
Podcasts
E-Handbooks
Industry News
Magazine Archives
Contact
Newsletter Subscription
Contact Us
Advertise
Follow us on
https://www.facebook.com/pages/Pharmaceutical-Manufacturing/140261116014887
http://www.linkedin.com/groups?gid=1813799
http://twitter.com/PharmaMfg
QRM Process
Pharmaceutical Manufacturing: Is It the Antithesis of Creative Destruction?
PAT and QbD can only move forward if the industry sheds its habit of QbA (i.e., quality by analysis)
Girish Malhotra
July 16, 2008
About the Author
Girish Malhotra
PE
Sign up for our eNewsletters
Get the latest news and updates
Sign Up
Related
UK pharmaceuticals exempt from tariffs in US drug pricing agreement
Agilent’s integration of recently acquired Biovectra remains a work in progress
Sponsored
2026 Manufacturing Pharma Trends for Life Sciences
Sponsored
2026 AI Trends in Life Sciences
Trending
Cell and gene therapies take two steps forward, one step back
Analysis of FDA drug approvals indicates favorable longer-term trend for CDMOs
Recipharm CEO says 2025 was ‘not an easy year’ for the CDMO
Sponsored Picks
Sponsored
2026 Manufacturing Pharma Trends for Life Sciences
Sponsored
2026 AI Trends in Life Sciences
Sponsored
2026 Manufacturing Medical Device Trends for Life Sciences
Load More Content